These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 27965478)

  • 1. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.
    Chung KH; Ryu JK; Son JH; Lee JW; Jang DK; Lee SH; Kim YT
    Gut Liver; 2017 Mar; 11(2):298-305. PubMed ID: 27965478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
    Kim SH; Shin SJ; Kim SY; Lee SH; Park YS; Park SH; Lee KH; Kim TW; Hong YS; Ahn JB
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):91-7. PubMed ID: 21607556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer.
    Berk V; Ozdemir N; Ozkan M; Aksoy S; Turan N; Inal A; Balakan O; Yasar N; Unal OU; Benekli M; Durnali A; Colak D; Sonmez OU
    Hepatogastroenterology; 2012; 59(120):2635-9. PubMed ID: 22534542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
    Boeck S; Hoehler T; Seipelt G; Mahlberg R; Wein A; Hochhaus A; Boeck HP; Schmid B; Kettner E; Stauch M; Lordick F; Ko Y; Geissler M; Schoppmeyer K; Kojouharoff G; Golf A; Neugebauer S; Heinemann V
    Ann Oncol; 2008 Feb; 19(2):340-7. PubMed ID: 17962204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer.
    Bayoglu IV; Varol U; Yildiz I; Muslu U; Alacacioglu A; Kucukzeybek Y; Akyol M; Demir L; Dirican A; Cokmert S; Yildiz Y; Karabulut B; Uslu R; Tarhan MO
    Asian Pac J Cancer Prev; 2014; 15(17):7119-23. PubMed ID: 25227800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
    Maier-Stocker C; Bitzer M; Malek NP; Plentz RR
    Scand J Gastroenterol; 2014 Dec; 49(12):1480-5. PubMed ID: 25390691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
    de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
    Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
    Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
    Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
    Doi T; Boku N; Kato K; Komatsu Y; Yamaguchi K; Muro K; Hamamoto Y; Sato A; Koizumi W; Mizunuma N; Takiuchi H
    Jpn J Clin Oncol; 2010 Oct; 40(10):913-20. PubMed ID: 20462981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
    Mukherjee S; Hurt CN; Bridgewater J; Falk S; Cummins S; Wasan H; Crosby T; Jephcott C; Roy R; Radhakrishna G; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T
    Lancet Oncol; 2013 Apr; 14(4):317-26. PubMed ID: 23474363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
    Hess V; Pratsch S; Potthast S; Lee L; Winterhalder R; Widmer L; Cescato C; Lohri A; Jost L; Stillhart P; Pestalozzi B; Herrmann R
    Ann Oncol; 2010 Dec; 21(12):2390-2395. PubMed ID: 20444846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.
    Xiong HQ; Varadhachary GR; Blais JC; Hess KR; Abbruzzese JL; Wolff RA
    Cancer; 2008 Oct; 113(8):2046-52. PubMed ID: 18756532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
    Kim ST; Kang JH; Lee J; Lee HW; Oh SY; Jang JS; Lee MA; Sohn BS; Yoon SY; Choi HJ; Hong JH; Kim MJ; Kim S; Park YS; Park JO; Lim HY
    Ann Oncol; 2019 May; 30(5):788-795. PubMed ID: 30785198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
    Neoptolemos JP; Palmer DH; Ghaneh P; Psarelli EE; Valle JW; Halloran CM; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S; Meyer T; Gillmore R; Anthoney A; Lind P; Glimelius B; Falk S; Izbicki JR; Middleton GW; Cummins S; Ross PJ; Wasan H; McDonald A; Crosby T; Ma YT; Patel K; Sherriff D; Soomal R; Borg D; Sothi S; Hammel P; Hackert T; Jackson R; Büchler MW;
    Lancet; 2017 Mar; 389(10073):1011-1024. PubMed ID: 28129987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation.
    Hazard L; Jones K; Shaban A; Anker C; Scaife C; Weis J; Mulvihill S
    J Gastrointest Cancer; 2012 Jun; 43(2):258-66. PubMed ID: 21243531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.
    Tan BR; Brenner WS; Picus J; Marsh S; Gao F; Fournier C; Fracasso PM; James J; Yen-Revollo JL; McLeod HL
    Ann Oncol; 2008 Oct; 19(10):1742-8. PubMed ID: 18534963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
    J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer.
    Isayama H; Nakai Y; Yamamoto K; Sasaki T; Mizuno S; Yagioka H; Yashima Y; Kawakubo K; Kogure H; Arizumi T; Togawa O; Ito Y; Matsubara S; Yamamoto N; Sasahira N; Hirano K; Tsujino T; Tada M; Omata M; Koike K
    Oncology; 2011; 80(1-2):97-101. PubMed ID: 21677453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.